GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (GREY:OBSEF) » Definitions » Shares Outstanding (EOP)

ObsEva (ObsEva) Shares Outstanding (EOP) : 107.71 Mil (As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is ObsEva Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. ObsEva's shares outstanding for the quarter that ended in Dec. 2022 was 107.71 Mil.

ObsEva's quarterly shares outstanding increased from Sep. 2022 (104.02 Mil) to Dec. 2022 (107.71 Mil). It means ObsEva issued new shares from Sep. 2022 to Dec. 2022 .

ObsEva's annual shares outstanding increased from Dec. 2021 (79.96 Mil) to Dec. 2022 (107.71 Mil). It means ObsEva issued new shares from Dec. 2021 to Dec. 2022 .


ObsEva Shares Outstanding (EOP) Historical Data

The historical data trend for ObsEva's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva Shares Outstanding (EOP) Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only 43.44 44.59 57.55 79.96 107.71

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.96 83.70 84.50 104.02 107.71

Competitive Comparison of ObsEva's Shares Outstanding (EOP)

For the Biotechnology subindustry, ObsEva's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ObsEva's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where ObsEva's Shares Outstanding (EOP) falls into.



ObsEva Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


ObsEva  (GREY:OBSEF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


ObsEva Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of ObsEva's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


ObsEva (ObsEva) Business Description

Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.
Executives
William Michael Brown officer: Chief Financial Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Anne Vanlent director C/O BARRIER THERAPEUTICS, INC., 600 COLLEGE ROAD EAST, SUITE 3200, PRINCETON NJ 08540
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Brian O'callaghan director, officer: Chief Executive Officer 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ernest Loumaye director C/O OBSEVA SA, CHEMIN DES AULX, 12, OLAN-LES-OUATES, GENEVA V8 1228
Catarina Edfjall director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 0000000000
Annette Clancy director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228
Stephanie Clare Brown director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228

ObsEva (ObsEva) Headlines

From GuruFocus